MedPath

The Vaccination Cohort Study on: 1. Immunologic Protection after Vaccination of Immune-compromised Patients 2. Assessment of the Infection Rate after International Travel

Withdrawn
Conditions
Travellers vaccination
10019815
Registration Number
NL-OMON38641
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
200
Inclusion Criteria

All individuals, irrespective of age, sex and underlying illness visiting the Erasmus MC *vaccination and travel clinic* requiring travel related, medically indicated or voluntary vaccination(s)

Exclusion Criteria

No informed consent

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The antibody titer after vaccination of immune compromised patients compared to<br /><br>immunocompetent patients and the incidence of infectious diseases during travel</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>1a The capability of naïve memory B cells to generate an<br /><br>antibody response after live, conjugated and polysaccharide vaccine dose<br /><br>increase in case of non-responders<br /><br>1b Dendritic cell function and antigen presentation properties<br /><br>1c CD8+ cytotoxic properties<br /><br>1d Waning effects of vaccines by the presence of a prolonged (i.e. after 6<br /><br>months) qualitative antibody response by detecting high affinitive IgG<br /><br>antibodies in serum as well as B-cell reactivation properties </p><br>
© Copyright 2025. All Rights Reserved by MedPath